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Dimeric positive allosteric modulators of iono-
tropic glutamate receptors were designed,
synthesized, and characterized pharmacologi-
cally in electrophysiological experiments. The
designed compounds are dimers of arylpropyl-
sulfonamides and have been constructed with-
out a linker. The monomeric arylpropylsulfona-
mides were derived from known modulators
and target the cyclothiazide-binding site at the
AMPA receptors. The three stereoisomers—
R,R, meso, and S,S—of the two constructed
dimers were prepared, and in vitro testing
showed the R,R forms to be the most potent
stereoisomers. The biarylpropylsulfonamides
have dramatically increased potencies, more
than three orders of magnitude higher than the
corresponding monomers. Dimer (R,R)-2a was
cocrystallized with the GluR2-S1S2J construct,
and an X-ray crystallographic analysis showed
(R,R)-2a to bridge two identical binding pockets
on two neighboring GluR2 subunits. Thus, this
is biostructural evidence of a homomeric dimer
bridging two identical receptor-binding sites.
INTRODUCTION
The medicinal chemistry concept of ligand dimerization
is attractive for a number of reasons. The most obvious
one is potentially increased affinity, because, for example,
many receptors and transporters exist as dimers or higher
oligomers, and dimeric ligands may bridge such oligo-
mers. The increase in overall affinity is caused by the syn-
ergy that occurs whenever two fragments with affinity are
covalently linked. The most well-known example is from
the immune system, in which immunoglobulins like IgG
are Nature’s own dimers, linking two epitope-recognizing
fragments together.
The hypothesis that the affinity of a bivalent molecule
will be greater than the sum of its fragments was proposed1294 Chemistry & Biology 14, 1294–1303, November 2007 ª20by Page and Jencks [1, 2]. Assuming that the translational
and rotational entropy of each fragment in a symmetrical
dimer equals the total translational and rotational entropy
for the bivalent molecule, and thus is independent of
molecular weight, the loss of entropy will decrease upon
joining the fragments. The sumof the affinities for two frag-
ments binding to two identical binding sites will include
two unfavorable rigid-body rotational and translational
entropy contributions, whereas the affinity for a bivalent
molecule in which the two fragments are linked will include
only one unfavorable term. To estimate this term, Murray
and Verdonk used experimental data including affinities
for the fragments as well as for the molecule with the frag-
ments joined together. The unfavorable rotational and
translational entropy contribution to binding was esti-
mated to be 15–20 kJ/mol, which corresponds to three
orders of magnitude in affinity [3].
The dimerization of ligands has also served other pur-
poses: improved pharmacokinetic properties, potency,
solubility, and selectivity have been observed [4, 5]. In
the early 80s, Portoghese and coworkers used the dimer-
ization of opioid receptor ligands to demonstrate the exis-
tence of functional, dimeric G-protein-coupled receptors
[6, 7]. Since then, similar approaches have been pursued
in many other areas of medicinal chemistry [8].
Despite numerous examples, of which several clearly
indicate that two equal binding sites are occupied by
dimeric ligands, there has, so far, been no direct structural
evidence for this. Here, to our knowledge, we provide the
first structural evidence of a dimeric ligand that occupies
two equal binding sites. The dimeric ligand was designed
by using computational chemistry and targets the iono-
tropic glutamate receptors (iGluRs), one of the key players
in neurotransmission in the brain. More specifically, the
designed ligand targets the cyclothiazide (CTZ)-binding
site at 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)pro-
pionic acid (AMPA) receptors GluR1–4. A soluble form of
the extracellular ligand-binding core of GluR2 has been
prepared [9], and a number of structures in complex with
various agonists [9–11] and antagonists [9, 12, 13] have
been determined in recent years. CTZ is a well-character-
ized positive allosteric modulator of AMPA receptors, and
the structure of CTZ in complex with GluR2 showed that
the CTZ-binding site is located at the interface between07 Elsevier Ltd All rights reserved
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Structural Proof of Dimeric LigandFigure 1. Known Modulators of AMPA
Receptors as Well as Designed Mono-
meric 1a,b and Dimeric Compounds
2a,b
R1 is either a methyl group or an isopropyl
group. R2 can be various substituents, as
reported by Ornstein et al. [17].two receptor subunits [14]. The aim of this study was to
obtain potent and selective ligands, which are of great
interest both as pharmacological tools and as potential
therapeutics. The homodimeric ligands reported here
were synthesized and pharmacologically characterized at
cloned rat GluR1–4. By using X-ray crystallography, the
homodimeric ligand was shown to bridge two identical
CTZ-binding sites.
RESULTS AND DISCUSSION
Design
At present, crystal structures of the GluR2 ligand-binding
core are available in complex with three positive allosteric
AMPA receptor modulators: CTZ [14], aniracetam, and
CX614 [15] (Figure 1). All three compounds bind at a
two-fold symmetrical dimer interface, with the symmetry
axis down through the center of the dimer interface. Two
molecules of CTZ bind to two identical and symmetrical
sites, which contain an N775S mutation in the GluR2
construct. These mutations cause the GluR2 construct
to resemble the receptor flip splice form, which is more
sensitive to CTZ. Aniracetam and CX614 bind in the region
between and overlapping the two CTZ sites.
A recent computational study described a potential
binding mode of a series of biarylpropylsulfonamide
(Figure 1) allosteric AMPA receptor modulators [16] and
utilized published structure-activity data [17]. It was
hypothesized that the center of the biaryl moiety of such
compounds is located close to the symmetry axis of the
GluR2 dimer interface, and that the alkylsulfonamide moi-
ety binds in one of the CTZ sites. This provided the basis
for the design of a symmetrical allosteric modulator ex-
tending into both CTZ sites with a symmetrical binding
mode (Figure 2).
The design of dimer 2a (Figure 1) was based on the
available structural information and the computational
study mentioned above. Computational docking of 2a
was set up to test the hypothesis of a symmetrical binding
mode. The crystal structure of aniracetam in complex with
a GluR2 construct (PDB code: 2AL5) [15] was selected for
the docking studies, because it contains specific side
chain conformations expected to be important for the
binding of 2a. Previous results have shown that a biaryl-
propylsulfonamide modulator displays preference for the
flip splice form of the AMPA receptors [18]. Assuming
the same preference for compound 2a, an amino acidChemistry & Biology 14, 1294–130replacement (N775S) was made in the structure used for
docking to mimic the flip splice form. 2a contains two
chiral centers, which result in the sulfonamide hydrogen
atoms and nitrogen lone pairs changing positions due to
the inversion. Ensuring symmetry, the three possible con-
figurations of 2awere prepared and docked into the dimer
interface of the GluR2 crystal structure, and the output
poses showed that both the R,R and S,S stereoisomers
would fit the binding site. In both cases, a symmetrical
binding mode in which the biaryl moiety was located at
the center of the dimer interface and the methyl sulfon-
amide moieties extended into the CTZ sites was observed
(Figure 2). Compound 2b (Figure 3) was designed on the
basis of results obtained withmonomeric modulators (Fig-
ure 1) [17]. A structurally related asymmetric analog of
compound 2a is in clinical trials [19], and, while writing
this manuscript, a synthesis of this asymmetric analog
was published [20].
The dockings clearly indicated that 2a can bind in both
CTZ sites in a symmetrical binding mode, and prompted
Figure 2. The Design of Dimeric Compounds
(A) Binding mode of CTZ (gray carbons) and aniracetam (green car-
bons: two overlapping orientations are present in the structure, each
with an occupancy of 0.5) in the symmetrical dimer interface of the
ligand-binding core of GluR2.
(B) Predicted binding mode of (R,R)-2a (cyan carbons) superimposed
on the binding mode of CTZ (gray carbons). Compound 2b was de-
signed on the basis of results obtained with analogs of known biaryl-
propylsulfonamides (Figure 1) described by Ornstein et al. [17].3, November 2007 ª2007 Elsevier Ltd All rights reserved 1295
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(i) LiHMDS, THF,78C; (ii) BH3S(CH3)2, THF, reflux; (iii) RSO2Cl, TEA, CH2Cl2, 0C ; (iv) H5IO6, I2, conc. H2SO4, AcOH, H2O, 60C; (v) Aryl halide, Aryl
boronic ester, PdCl2(PPh3)2, PPh3, K2CO3, H2O, 1.4-dioxane, 80
C; (vi) 1g, LiCl, Pd(OAc)2, In, DMF, 100C; (vii) chiral HPLC.us to synthesize and characterize the compounds in order
to test the hypothesis.
Chemistry
The designed ligands were synthesized according to the
procedures outlined in Figure 3. Optically pure 1a,b were
synthesized by using (R)- and (S)-5c, whereas 2a,b initially
were synthesized as mixtures of stereoisomers, by utiliz-
ing standard lithium-based deprotonation for the introduc-
tion of an a-methyl group on 3a,b, followed by reduction to
give 5a,b, analogous to previously reported procedures
[21]. Addition of an alkyl sulfonyl moiety afforded 1a–f.
The bivalent ligands were formed from 1c–f via palla-
dium-catalyzed Suzuki crosscoupling conditions and af-
forded 2a,b as mixtures of stereoisomers in good yields.1296 Chemistry & Biology 14, 1294–1303, November 2007 ª20Using semipreparative chiral HPLC, we were able to iden-
tify systems with excellent separation (Rt = 35, 62, and
87 min for (R,R)-2a,meso-2a, and (S,S)-2a, respectively;
Rt = 25, 60, and 100min for (R,R)-2b,meso-2b, and (S,S)-
2b, respectively), enabling facile separation of the stereo-
isomers as well as ee determinations.
Upon scaling up the syntheses, we decided to synthe-
size only the most potent enantiomer, (R,R)-2a, and to
reduce the number of synthetic steps in order to increase
the overall yield. An optically pure startingmaterial, (R)-1a,
was chosen and selectively iodinated in the para position,
in analogy to the procedure previously reported [22] to
yield (R)-1g. Direct homocoupling with indium and palla-
dium catalysis [23] afforded (R,R)-2a in fair yield on the
gram scale.07 Elsevier Ltd All rights reserved
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Profiles of Biarylpropylsulfonamide Analogs 2a,b
Recombinant rat GluR1i, GluR2(Q)i, GluR2(Q)o, GluR3i,
and GluR4i were expressed in X. laevis oocytes; GluR2
and GluR3 contained Gly at the R/G editing site, whereas
GluR1 and GluR4 contained Arg. The potentiation of (S)-
Glu (10 mM) responses by 2a,b was measured by using
two-electrode voltage clamp electrophysiology. The
activity of the enantiomers of 1a,b was compared with
that of the pure stereoisomers of 2a,b at GluR2(Q)i (Ta-
ble 1). CTZ was employed as a reference compound
and gave an EC50 value (5.16 ± 0.36 mM) consistent with
a previously reported value (7.6 mM) [18].
Whereas themonomeric analogs (R)-1a, (S)-1a, (R)-1b,
and (S)-1b had very high or immeasurable EC50 values for
potentiation of (S)-Glu responses at GluR2(Q)i, the
Table 1. Pharmacological Profile of the Stereoisomers
of Biarylpropylsulfonamide Analogs 1a,b and 2a,b at
GluR2(Q)i Expressed in X. laevis Oocytes
Compound EC50 (mM) nH % Max. Pot.
a
(R)-1a (5) 1980 ± 285 1.37 ± 0.06 1023 ± 248
(S)-1a (11) >3000 — —
(R)-1b (5) 195 ± 13 1.26 ± 0.13 1097 ± 194
(S)-1b (6) 1485 ± 220 1.09 ± 0.04 792 ± 16
(R,R)-2a (9) 0.73 ± 0.13 1.36 ± 0.15 790 ± 87
meso-2a (10) 0.96 ± 0.14 1.29 ± 0.09 732 ± 99
(S,S)-2a (8) 3.10 ± 0.46 1.36 ± 0.09 221 ± 29
(R,R)-2b (10) 0.44 ± 0.06 1.40 ± 0.08 796 ± 135
meso-2b (8) 0.85 ± 0.18 1.61 ± 0.09 1056 ± 265
(S,S)-2b (11) 1.68 ± 0.27 2.66 ± 0.40 524 ± 59
CTZ (5) 5.16 ± 0.36 1.47 ± 0.04 324 ± 48
Means ± SEM are presented; the number of experiments
performed (n) for each compound is indicated in parentheses.
‘‘—,’’ immeasurable.
a Percentage maximum potentiation of a 10 mM (S)-Glu
response.Chemistry & Biology 14, 1294–130corresponding dimeric analogs (R,R)-2a, (S,S)-2a,
meso-2a, (R,R)-2b, (S,S)-2b, and meso-2b showed
very low EC50 values; some values were more than three
orders of magnitude lower than the values for the corre-
sponding monomer (Table 1). For 2a and 2b, the R,R
enantiomers were more potent than the corresponding
S,S enantiomers (p < 0.05). There was no significant differ-
ence in the potency of (R,R)-2a compared to (R,R)-2b.
Potentiation by 2a (themixture of stereoisomers) was eval-
uated at holding potentials from 10 mV to 90 mV, and
no voltage dependency was observed (data not shown).
A comparison of the maximal potentiation produced by
30 mM 2a (the mixture of stereoisomers) divided by the
maximal potentiation given by 100 mM CTZ at GluR2(Q)i
gave a value of 1.96 ± 0.05 (mean ± SEM, n = 14).
Subtype Selectivity of 2a
(R,R)-2a was evaluated for subtype selectivity (Table 2).
(R,R)-2a showed only small differences in potency be-
tween the receptor subtypes GluR1i–4i. At GluR1i and3i,
(R,R)-2a had similar potency, which was lower than that
at GluR2(Q)i and 4i. However, there was no flip versus
flop selectivity when GluR2(Q)i and GluR2(Q)o were com-
pared (Figure 4; Table 2).
X-Ray Structure Determination of (R,R)-2a
in Complex with the Ligand-Binding Core of GluR2
As a proof of concept, we set out to crystallize (R,R)-2a in
complex with the ligand-binding core of GluR2 and (S)-Glu
by using the flip-like variant of GluR2-S1S2J (iGluR2-
S1S2J-N775S) [14]. (R,R)-2a was chosen for crystalliza-
tion because of a higher aqueous solubility compared to
(R,R)-2b. Indeed, (R,R)-2a was found to bind at the dimer
interface of GluR2-S1S2J-N775S and to bridge the two
allosteric binding sites previously shown to accommodate
two molecules of CTZ (Figure 5A). Thus, it was shown that
the designed symmetrical allosteric modulator of GluR2
extended into both CTZ-binding sites with a symmetrical
binding mode.
(S)-Glu introduced full domain closure (molecule A:
22.2; molecule B: 21.0) in GluR2-S1S2J-N775S in the
presence of the allosteric modulator (R,R)-2a. The dimer-
interface-accessible surface area is 760 A˚2 and isTable 2. Pharmacological Profile of (R,R)-2a and (S)-Glu
(R,R)-2a (S)-Glu
EC50 (mM) nH % Max. Pot.
a EC50 (mM) nH
GluR1i 1.52 ± 0.15 (8) 2.16 ± 0.10 (8) 1,335 ± 144 (8) 12.5 ± 1.4 (9) 0.63 ± 0.07 (9)
GluR2(Q)i 0.73 ± 0.13
b,c (9) 1.36 ± 0.15 (9) 790 ± 87 (9) 14.7 ± 1.4 (13) 0.90 ± 0.04 (13)
GluR2(Q)o 0.64 ± 0.13 (7) 1.30 ± 0.10 (7) 804 ± 88 (7) 1.52 ± 0.30
d (10) 1.06 ± 0.04 (10)
GluR3i 1.90 ± 0.13 (7) 2.54 ± 0.23 (7) 2,217 ± 513 (7) 21.2 ± 1.4 (11) 1.01 ± 0.02 (11)
GluR4i 0.87 ± 0.11
b,c (8) 1.80 ± 0.21 (8) 383 ± 38 (8) 19.6 ± 2.7 (14) 0.57 ± 0.01 (14)
Mean ± SEM values are presented with the n value indicated in parentheses.
a Percentage maximum potentiation.
b Statistically significantly different from GluR1i (p < 0.05, one-way ANOVA).
c Statistically significantly different from GluR3i (p < 0.05, one-way ANOVA).
d Statistically significantly different from GluR2(Q)i (p < 0.05, one-way ANOVA).3, November 2007 ª2007 Elsevier Ltd All rights reserved 1297
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Subtype selectivity profile of (R,R)-2a. Shown
are mean ± SEM responses of data pooled
from all experiments by normalizing the mea-
sured potentiation to the calculated maximal
potentiation for each oocyte. GluR2(Q)i (open
circles, dashed line); GluR2(Q)o (closed circles,
dotted line). Inset: traces from one GluR2(Q)i
experiment. See Table 2 for EC50 values.comprised of three regions: Ile502-Ser518, Phe679-
Ile685, and Leu748-Lys782. In total, six hydrogen bonds
(Leu504N[A]-Glu776OE2[B], Glu507OE1[A]-Asn768ND2
[A], and Phe512O[A]-Lys514NZ[B], and vice versa) and1298 Chemistry & Biology 14, 1294–1303, November 2007 ª20two salt bridges (Glu507OE1[A]-Lys514NZ[B] and vice
versa) are formed between the two protomers, and this
structure is similar to that of GluR2-S1S2J-N775S in
complex with CTZ (PDB code: 1LBC) [14].Figure 5. Bridging of Two Allosteric
Binding Sites within the Ligand-Binding
Core of GluR2 by (R,R)-2a
(A) The dimeric structure of GluR2-S1S2J-
N775S in complex with (S)-Glu and (R,R)-2a.
A ribbon representation of the two protomers
comprising the dimer is shown in cyan (mole-
cule A) and green (molecule B). Accordingly,
a transparent surface representation of resi-
dues in the vicinity (max. 4 A˚) of (R,R)-2a is
shown. (R,R)-2a (magenta) and (S)-Glu (yellow)
are displayed in stick representation. Two wa-
ter molecules mediating interactions between
(R,R)-2a and protein are shown as red
spheres.
(B) Close-up view of one half of the symmetric
(R,R)-2a molecule located in the binding site
(shown in magenta stick representation). The
view is different from that in Figure 4A). A trans-
parent surface representation of the amino
acid residues interacting with (R,R)-2a is
shown (molecule A: cyan; molecule B: green).
All amino acid residues within 4 A˚ of (R,R)-2a
are shown. The atoms have been colored ac-
cording to type. The interacting water molecule
is shown as a red sphere. Hydrogen bonds
from (R,R)-2a are displayed as stippled lines
(max. 3.5 A˚).
(C) Close-up view of the CTZ-binding mode in
GluR2-S1S2J-N775S (PDB code: 1LBC). The
view is similar to that in Figure 4B). CTZ
is shown in magenta stick representation. A
transparent surface representation of the resi-
dues interacting with CTZ is shown (molecule
A: cyan; molecule C: green). All amino acid res-
idues within 4 A˚ of CTZ are shown. The atoms
have been colored according to type. The in-
teracting water molecules are shown as red
spheres.07 Elsevier Ltd All rights reserved
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allosteric binding sites comprised of the same 10 inter-
face residues (Ile502[B], Lys514[A], Pro515[A],
Phe516[A], Met517[A], Ser518[A], Ser750[B], Lys751[B],
Gly752[B], and Leu772[A], and vice versa) (Figure 5). The
two sulfonamide moieties of (R,R)-2a form the same hy-
drogen-bonding pattern to the protein, whereas a slightly
different location of the water molecule mediating hydro-
gen bonds between the sulfonamide oxygen atoms and
the carbonyl oxygen atom of Ile502 and the nitrogen
atom of Gly752 of the same protomer is seen. Hydrogen
bonds are formed directly with residues Pro515 and
Gly752: from the sulfonamide nitrogen atom of (R,R)-2a
to the oxygen atom of Pro515 of one protomer, and from
the sulfonamide oxygen atom to the nitrogen atom of
Gly752 of the other protomer. Hence, the sulfonamide
moiety is anchoring the allosteric modulator to both mole-
cules comprising the dimer. The two phenyl moieties of
(R,R)-2a function to bridge the two sites and make van
der Waals interactions with residues Pro515-Ser518 and
Ser750-Gly752 of both molecules. When comparing the
structures of GluR2-S1S2J-N775S in complex with
(R,R)-2a (Figure 5B) and CTZ (Figure 5C), it is evident
that the sulfonamidemoiety of (R,R)-2a binds at a position
similar to that of the norbornene moiety of CTZ. However,
the sulfonamide nitrogen atoms of the two ligands are lo-
cated at equivalent positions in the two structures, which
allows for hydrogen-bond formation to the same protein
residue (Pro515).
SIGNIFICANCE
Positive allosteric modulators of AMPA receptors
have received growing interest due to their potential
clinical use for treatment of disorders such as schizo-
phrenia, depression, and Alzheimer’s disease [24]. In
order to probe the hypothesis that homodimeric
ligands may bind to two identical binding sites, we
designed dimeric biarylpropylsulfonamides. Compu-
tational docking experiments of the methyl sulfon-
amide dimer 2a in the CTZ ligand-binding core of
GluR2 showed a good fit in two neighboring identical
binding sites, and the stereoisomers of 2a were
consequently synthesized. When comparing the activ-
ity of the homodimer to the corresponding monomer,
it was apparent that an increase in potency (decreased
EC50) of three orders of magnitude was obtained with
the homodimer. As a proof-of-concept, (R,R)-2a was
cocrystallized with the GluR2-S1S2J-N775S construct
and was shown by X-ray crystallography to bridge two
identical allosteric binding sites in two neighboring
GluR2 subunits. Thus, this is the first, to our knowl-
edge, structural evidence supporting the often used
dimer approach within medicinal chemistry. Several
explanations have been proposed for the improved
pharmacological activities obtained by the dimer
approach. One working hypothesis is the interaction
of dimers with two neighboring identical receptor-
binding sites simultaneously, and another, more likely,Chemistry & Biology 14, 1294–130hypothesis is the interaction with a receptor-binding
site and a secondary nonidentical binding site in the vi-
cinity [8]. Obviously, in the present example, the mech-
anism for the binding of dimer (R,R)-2a in GluR2 is the
simultaneous interaction with two identical allosteric
binding sites. The design of dimeric ligands may be
a generally useful way forward in the search for new,
potent, selective therapeutics in the treatment of
various neurological disorders.
EXPERIMENTAL PROCEDURES
Design
TheGluR2-S1S2Jcrystal structure in complexwith aniracetam [15]was
retrieved from the Protein Data Bank (PDB code: 2AL5) and imported
intoMaestro [25]. Asn775 of both chains A andCwas changed to a ser-
ine, aniracetam andwater molecules were deleted, the atom types and
bond orders of the agonist were corrected, and hydrogen atoms were
added. The positions of polar hydrogen atoms were optimized by run-
ning the first step of refinement in the protein preparation utility of Glide
[26], andagridwaspreparedwith thecenterdefinedby residuesPro515
and Ser518. All three midpoint box diameters were set to 14 A˚, and the
length of ligands was set to 10 A˚. All configurations of compound 2a
were built inMaestro andwere energyminimized by usingMacroModel
[27]with theMMFFs forcefieldand theTNCGminimizationmethod. The
calculations were performed without a cut off distance for nonbonded
interactions by using the build-in aqueous solvationmodel. The stereo-
isomers of 2a were then docked in GluR2 by using Glide and the pre-
pared grid, employing a scaling factor of 0.7 for all ligand atoms. The
maximal output was set to 20 poses per ligand.
Synthesis and Characterization
General
All reactions involving air-sensitive reactants were performed under N2
by using septum-syringe techniques. Glassware was flame dried
under vacuum prior to use. All solvents used for air-sensitive reactions
were dried over molecular sieves (3 or 4 A˚) and tested on a Fisher ap-
paratus to be below 10 ppm water. Chemicals were purchased from
Fluka, Aldrich, or Frontier chemicals and were used without further
purification.
1H-NMR and 13C-NMR spectra were recorded on a Varian Mercury
(300 MHz), a Varian Gemini (300 MHz), or a DRX (300 or 400 MHz)
spectrometer in CDCl3, CD3OD, or DMSO-d6 by using either TMS or
solvent as the internal standard. Chemical shifts (d) are expressed in
ppm and coupling constants (J) in Hertz. Optical rotation was mea-
sured on a Perkin Elmer 241 Polarimeter. Commercially available
TLC plates (silica gel 60 F254) were used for TLC analyses, and the
spots were visualized by using UV light (254 nm) or either an alkaline
potassium permanganate or a ninhydrin solution for soaking the
plates. Melting points were determined in open capillaries by using
a Buchi B-545 melting point apparatus or a SRS Optimelt MPA100
apparatus and are uncorrected. Microanalyses were performed by
Mikro Kemi AB, Seminariegatan, Uppsala, Sweden or by J. Theiner,
Microanalytical Laboratory, Dept. of Physical Chemistry, University
of Vienna, Austria and agree with the theoretical values ±0.4%.
(R,S)-2-(4-Bromophenyl)Propanenitrile, (R,S)-4a
4-Bromobenzylacetonitrile (3a) (9.00 g; 45.91 mmol) was dissolved in
THF (60 ml; 0.75 M solution) and cooled to 78C, and LiHMDS
(48.20 ml 1 M in THF; 48.20 mmol) was added dropwise while stirring.
Stirring was continued at78C for 1 hr before the addition of iodome-
thane (3.01 ml; 6.84 g; 48.20 mmol). The reaction was stirred at78C
for another hour before it was allowed to warm to room temperature
overnight. The reaction was poured into H2O (900 ml), acidified with
1MHCl, and extractedwith EtOAc (33 600ml). The combined organic
phases were washed with H2O (150 ml) and brine (150 ml), dried
(MgSO4), and filtered, and the solvent was evaporated to yield3, November 2007 ª2007 Elsevier Ltd All rights reserved 1299
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Structural Proof of Dimeric Ligand(RS)-4a as a red oil (9.26 g; 96%). 1H-NMR (300 MHz) in CDCl3 d 1.65
(d, J = 6 Hz, 3H); 3.87 (q, J = 6Hz, 1H); 7.22 (d, J = 9 Hz, 2H); 7.50 (d, J =
9 Hz, 2H); 13C-NMR (100MHz) in CDCl3 d 21.69; 29.40; 127.31; 128.86;
130.25; 132.33; 132.67.
(R,S)-2-(4-[4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-
yl]Phenyl)Propanenitrile, (R,S)-4b
(R,S)-4b was synthesized and purified analogously to (R,S)-4a
by using 2-(4-[4,4,5,5-tetramethyl-1-3-2-dioxaborolan-2-yl]phenyl)
acetonitrile (10.00 g; 41.13 mmol) as starting material. Crude
(R,S)-4b was obtained as a yellow oil that crystallized upon standing,
mp 80.5C–81.0C (10.51 g; 99%). 1H-NMR (300 MHz) in CDCl3 d 1.35
(s, 12H); 1.64 (d, J = 6 Hz, 3H); 3.90 (q, J = 6 Hz, 1H); 7.37 (d,
J = 9 Hz, 2H); 7.83 (d, J = 9 Hz, 2H); 13C-NMR (75 MHz) in
CDCl3 d 21.45; 24.86; 31.42; 83.99; 121.38; 126.04; 134.92; 135.60;
139.97.
(R,S)-2-(4-Bromophenyl)Propan-1-Amine Hydrochloride,
(R,S)-5a
(R,S)-4a (3.95 g; 18.80 mmol) was dissolved in THF (0.5 M solution),
and BH3S(CH3)2 (10.34 ml; 2 M in THF, 20.68 mmol) was added.
The reaction was heated to reflux for 3 hr. After cooling to room tem-
perature, the reaction was treated with sat. HCl in Et2O until precipita-
tion started. Filtration and drying afforded pure (R,S)-5a as white
crystals, mp 201.5C–202.9C, (4.69 g; 99%). 1H-NMR (300 MHz) in
DMSO-d6 d 1.26 (d, J = 6 Hz, 3H); 2.93–3.12 (m, 1H); 3.48–3.54
(m, 1H); 3.66–3.74 (m, 1H); 7.28 (d, J = 6 Hz, 2H); 7.50 (d, J = 6 Hz,
2H); 8.08 (bs, 2H); 13C-NMR (75 MHz) in DMSO-d6 d 19.51; 37.24;
44.95; 120.31; 129.96; 131.83; 142.56.
(R,S)-2-(4-[4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-
yl]Phenyl)Propan-1-Amine Hydrochloride, (R,S)-5b
(R,S)-5b was synthesized analogously to 5a by using 4b (4.35 g; 16.92
mmol) as starting material. Pure (R,S)-5b was obtained as white
crystals, mp 79.5C–80.5C (5.01 g; 99%). 1H-NMR (300 MHz) in
CDCl3 d 1.25–1.32 (m, 15 H); 2.94–3.12 (m, 1H); 3.45–3.51 (m, 1H);
3.66–3.73 (m, 1H); 7.34 (d, J = 6 Hz, 2H); 7.65 (d, J = 6 Hz, 2H); 8.04
(bs, 2H); 13C-NMR (100 MHz) in CDCl3 d 22.44; 27.74; 40.75; 46.88;
86.86; 129.49; 130.08; 138.12; 147.98.
General Method for Addition of Alkane Sulfonyl Chloride to
Primary Amines to Give (R,S)-1a–f
2-Phenyl-1-propylamine or 2-phenyl-1-propylamine hydrochloride
(1 eq.) was dissolved or suspended in CH2Cl2 (0.25 M solution) and
cooled to 0C, and TEA (20% v/v with respect to CH2Cl2) was added.
Methyl or isopropyl sulfonyl chloride (1.5 eq.) was added dropwise,
and the reaction was stirred at 0C for 1 hr at room temperature over-
night. The reaction was diluted with Et2O to 53 the volume, and the
reaction was washed once with H2O, 0.2 M HCl, sat. NaHCO3, and
brine. The organic phase was dried (Na2SO4), filtered, and evaporated
to yield crude (R,S)-1a–f as oils.
(R)-N-(2-Phenylpropyl)Methanesulfonamide, (R)-1a
(R)-1a was synthesized according to the general method with (R)-5c
(6.00 g; 44.38 mmol) and methyl sulfonyl chloride (5.17 ml; 7.63 g;
66.57 mmol). Crude (R)-1a was purified via reverse-phase preparative
HPLC (Xterra column, water [0.1% TFA] and a CH3CN gradient of 5%–
95%over the course of 20min). (R)-1awas obtained as a clear, slightly
yellow oil (9.21 g; 97%). [a]24589 = +5.6
 (c 0.16, CH2Cl2).
1H-NMR (300
MHz) in CDCl3 d 1.36 (d, J = 9 Hz, 3H); 2.77 (s, 3H); 2.98–3.05 (m, 1H);
3.25–3.38 (m, 2H); 4.74 (bs, 1H); 7.26–7.41 (m, 5H); 13C-NMR (75 MHz)
in CDCl3 d 19.58; 40.50; 50.46; 53.46; 127.35; 127.71; 129.17; 143.70.
Analysis CHN(C10H15NO2S0.5 H2O, 0.15 C2HO2F3).
(S)-N-(2-Phenylpropyl)Methanesulfonamide, (S)-1a
(S)-1a was synthesized according to the general method with (R)-5c
(1.00 g; 7.40 mmol) and methyl sulfonyl chloride (0.86 ml; 1.27 g;
11.09 mmol). Crude (S)-1a was purified via FC (silica 60; eluent:
heptane with rising EtOAc gradient) to afford (S)-1a as clear, slightly
yellow oil (1.18 g; 75%). [a]23589 = 9.0 (c 0.75, CH2Cl2). 1H-NMR
(300 MHz) in CDCl3 d 1.32 (d, J = 9 Hz, 3H); 2.78 (s, 3H); 2.90–3.02
(m, 1H); 3.20–3.28 (m, 1H); 3.35–3.42 (m, 1H); 4.15 (bs, 1H); 7.20–
7.36 (m, 5H); 13C-NMR (100 MHz) in CDCl3 d 19.00; 40.31; 49.96;
53.46; 127.13; 127.28; 128.91; 142.02. Analysis CHN(C10H15NO2S).1300 Chemistry & Biology 14, 1294–1303, November 2007 ª20(R)-N-(2-Phenylpropyl)Propane-2-Sulfonamide, (R)-1b
(R)-1b was synthesized according to the general method with (R)-5c
(1.00 g; 7.40 mmol) and isopropyl sulfonyl chloride (1.26 ml; 1.61 g;
12.13 mmol). Crude (R)-1b was purified via reverse-phase preparative
HPLC (Xterra column, water [0.1% TFA] and a CH3CN gradient of 5%–
95%over the course of 20min). (R)-1bwas obtained as a clear, slightly
yellow oil (1.71 g; 96%). [a]24589 = +7.3
 (c 0.17, CH2Cl2).
1H-NMR
(400 MHz) in CDCl3 d 1.29 (d, J = 12 Hz, 3H); 1.32 (d, J = 9 Hz, 6H);
2.93–3.07 (m, 2H); 3.18–3.27 (m, 1H); 3.34–3.42 (m, 1H); 4.01 (bs,
1H); 7.20–7.27 (m, 3H); 7.33 (t, J = 6 Hz, 2H); 13C-NMR (100 MHz) in
CDCl3 d 14.71; 14.87; 16.98; 39.13; 48.32; 51.61; 125.24; 125.37;
127.09; 142.00. Analysis CHN(C12H19NO2S0.25 H2O).
(S)-N-(2-Phenylpropyl)Propane-2-Sulfonamide, (S)-1b
(S)-1b was synthesized according to the general method with (R)-5c
(1.00 g; 7.40 mmol) and isopropyl sulfonyl chloride (1.24 ml; 1.58 g;
11.94 mmol). Crude (S)-1b was purified by using FC (silica 60; eluent:
heptane with rising EtOAc gradient) and afforded (S)-1b as a clear oil
(1.43 g; 80%). [a]25589 = 11.1 (c 0.55, CH2Cl2). 1H-NMR (400 MHz)
in CDCl3 d 1.25 (d, J = 12 Hz, 3H); 1.30 (d, J = 9 Hz, 6H); 2.98–3.08
(m, 2H); 3.16–3.26 (m, 1H); 3.32–3.41 (m, 1H); 4.02 (bs, 1H); 7.21—
7.28 (m, 3H); 7.34 (t, J = 6 Hz, 2H); 13C-NMR (100 MHz) in CDCl3
d 14.53; 14.66; 17.16; 38.84; 48.39; 51.37; 125.17; 125.32; 126.99;
141.12. Analysis CHN(C12H19NO2S0.10 H2O0.10 C2HF3O2).
(R,S)-N-(2-[4-Bromophenyl]Propyl)Methanesulfonamide,
(R,S)-1c
(R,S)-1c was synthesized according to the general method with
(R,S)-5a (2.35 g; 9.38 mmol) and methyl sulfonyl chloride (1.28 ml;
1.89 mg; 16.46 mmol). (R,S)-1c was obtained as a red-brown oil
(2.71 g, 99%), which could be used without further purification.
1H-NMR (400 MHz) in CDCl3 d 1.28 (d, J = 9 Hz, 3H); 2.82 (s, 3H);
2.92–3.03 (m, 3H); 4.09 (bs, 1H); 7.10 (d, J = 9 Hz, 2H); 7.46 (d, J = 9
Hz, 2H); 13C-NMR (100 MHz) in CDCl3 d 18.86; 39.99; 40.49; 49.74;
121.00; 129.03; 132.03; 141.94. Analytical purification: CF (silica
60 H, eluent: heptane with rising EtOAc gradient) yielded pure (R,S)-
1c, which crystallized upon standing, mp = 74.5C–75.5C. Analysis
CHN(C10H14BrNO2S).
(R,S)-N-(2-[4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-
yl)Phenyl]Propyl)Methanesulfonamide, (R,S)-1d
(R,S)-1d was synthesized according to the general method with (R,S)-
5b (4.42 g; 14.85 mmol) and methyl sulfonyl chloride (1.97 ml; 2.91 g;
25.36mmol). Crude (R,S)-1dwas obtained as a yellow oil (4.89 g; 97%)
and was used without further purification. 1H-NMR (400 MHz) in CDCl3
d 1.30 (d, J = 12 Hz, 3H); 1.35 (s, 12H); 2.79 (s, 3H); 2.83–3.08 (m, 1H);
3.21–3.29 (m, 1H); 3.33–3.43 (m, 1H); 7.24 (d, J = 6 Hz, 2H); 7.77 (d,
J = 6 Hz, 2H); 13C-NMR (100 MHz) in CDCl3 d 18.91; 21.07; 31.53;
40.38; 49.79; 83.85; 126.69; 135.46; 146.17.
(R,S)-N-(2-[4-Bromophenyl]Propyl)Propane-2-Sulfonamide,
(R,S)-1e
(R,S)-1e was synthesized according to the general method with (R,S)-
5a (3.60 g; 14.37mmol) and isopropyl sulfonyl chloride (2.82ml; 3.60 g;
25.22 mmol). (R,S)-1e was obtained as a yellow, semicrystalline sub-
stance (4.37 g; 95%). 1H-NMR (400MHz) in CDCl3 d 1.18–1.34 (m, 9H);
2.70–3.48 (m, 4H); 7.09 (dd, J = 6 and 3 Hz, 2H); 7.47 (dd, J = 6 and 3
Hz, 2H); 13C-NMR (100 MHz) in CDCl3 d 16.63; 18.92; 40.49; 50.20;
53.57; 120.86; 129.12; 131.99; 142.08.
(R,S)-N-(2-[4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-
yl)Phenyl]Propyl)Propane-2-Sulfonamide, (R,S)-1f
(R,S)-1f was synthesized according to the general method with (R,S)-
5b (4.00 g; 13.44mmol) and isopropyl sulfonyl chloride (2.57ml; 3.28 g;
22.97 mmol). Crude (R,S)-1f was obtained as a yellow, semicrystaline
substance (4.00 g; 81%). 1H-NMR (400 MHz) in CDCl3 d 1.32 (m, 12H);
1.31–1.37 (m, 2H); 2.74–3.39 (m, 4H); 7.23 (dd, J = 6 and 3Hz, 2H); 7.78
(dd, J = 6 and 3 Hz, 2H); 13C-NMR (100 MHz) in CDCl3 d 14.21; 21.07;
24.86; 43.70; 60.41; 69.22; 83.71; 126.85; 135.10; 146.88.
(R)-N-(2-[4-Iodophenyl]Propyl)Methanesulfonamide,
(R)-1g
(R)-1a (8.0 g; 37.5 mmol) was dissolved in AcOH (44 ml) and was
treatedwith conc. H2SO4 (4.0 g; 2.22ml) and H2O (9.0ml) while stirring.07 Elsevier Ltd All rights reserved
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Structural Proof of Dimeric LigandTo this solution, H5IO6 (2.14 g; 9.38 mmol) was added, followed by I2
(4.76 g; 18.75 mmol), and the reaction was heated to 60C for 3 hr.
The reaction was allowed to reach 30C and esd added dropwise to
a solution of NaHSO3 (2.0 g) in sat. NaHCO3 (30 ml). The aqueous
solution was extracted with EtOAc (3 3 100 ml), and the combined
organic phases were dried (MgSO4). Hot (80
C) heptane (300 ml)
was added, and the EtOAc:heptane phase was concentrated under
reduced pressure at 70C to a total volume of 300 ml, at which point
crystals appeared. The reaction was left for 18 hr to allow precipitation
of (R)-1g. The crystals were filtered off, washed with heptane, and
dried to afford crude (R)-1g. According to 1H-NMR, 10% uncon-
verted (R)-1a was observed in the sample. Crude (R)-1g (12.01 g,
85%, corrected according to NMR) was used without further purifica-
tion. Mp 99C–100C. 1H-NMR (300 MHz) in CDCl3 1.45 (d, J = 6 Hz,
3H); 3.00 (s, 3H); 3.34–3.52 (m, 3H); 4.38 (bs, 1H); 7.15 (d, J = 9 Hz,
2H); 7.84 (d, J = 9 Hz, 2H); 13C-NMR (75 MHz) in CDCl3 d 19.37;
40.58; 40.97; 50.18; 92.73; 129.68; 138.29; 142.97.
(R,R)-, (S,S)-, and (Meso)-N,N-(2,20-[Biphenyl-4-40-
Diyl]Bis[Propane-2,1-Diyl])Dimethanesulfonamide, 2a
(R,S)-1c (2.43 g; 8.32mmol) was dissolved in 1.4-dioxane (0.05M), and
PdCl2(PPh3)2 (292 mg; 0.42 mmol; 5 mol%) and PPh3 (100 mg;
0.38 mmol; 5 mol%) were added. The mixture was stirred for 15 min
before the addition of K2CO3 (5.75 g; 41.58 mmol), (R,S)-1d (3.53 g;
10.40 mmol), and H2O (equal amount to 1.4-dioxane). The reaction
washeated to80C for 4days andallowed tocool to room temperature.
H2O (475ml) was added, and the mixture was extracted with Et2O (33
450ml). The combined organic phaseswerewashedwithH2O (150ml),
1 M NaOH (150 ml), and H2O (150 ml). Drying (Na2SO4), filtration, and
evaporation of the solvent afforded crude 2a as a light-yellow oil. CF
(silica 60 H, eluent: heptane with rising EtOAc gradient) yielded 2a as
a white, crystalline powder containing a mixture of stereoisomers
(937 mg; 86%). Mp 165C–174C. 1H-NMR (400 MHz) in CDCl3
d 1.36 (d, J = 9 Hz, 6H); 2.84 (s, 6H); 3.00–3.11 (m, 2H); 3.24–3.35 (m,
2H); 3.38–3.47 (m, 2H); 4.14 (bs, 2H); 7.31 (d, J = 6 Hz, 4H); 7.57 (d,
J = 6 Hz, 4H); 13C-NMR (100 MHz) in CDCl3 d 19.02; 40.05; 40.40;
49.91; 127.55; 127.78; 139.60; 142.02. 2a mixture of stereoisomers:
analysis CHN(C20H28N2O4S20.30 C7H160.25 C2HF3O2).
Chiral HPLC purification with a Daicel Chiralpak AS (2 3 25 cm)
column and 50:50 heptane:ethanol with a 7.00 ml/min flow afforded
the pure stereoisomers: Rt(R,R)-2a = 35 min, Rt(meso)-2a = 60 min,
and Rt(S,S)-2a = 87 min (for details, see the Supplemental Data avail-
able with this article online). (R,R)-2a: [a]25589 = +48
 (c 0.115, CH2Cl2);
meso-2a: [a]25589 = +2.1
 (c 0.095, CH2Cl2); (S,S)-2a[a]
25
589 = 50
(c 0.170, CH2Cl2). (R,R)-2a: mp 207.6
C–208.0C; (meso)-2a:
mp 192.7C–193.1C; (S,S)-2a: mp 202.3C–203.8C. Analysis
(R,R)-2a: CHN(C20H28N2O4S20.10 C7H160.10 C2HF3O2); (meso)-
2a: CHN(C20H28N2O4S20.15 C7H160.15 C2HF3O2); (S,S)-2a:
CHN(C20H28N2O4S20.20 C7H160.25 C2HF3O2).
(R,R)-, (S,S)-, and (Meso)-N,N-(2,20-[Biphenyl-4-40-
Diyl]Bis[Propane-2,1-Diyl])Dipropane-2-Sulfonamide, 2b
2b was synthesized and purified analogously to 2a by using (RS)-1e
(1.70 g; 5.31 mmol) and (RS)-1f (2.44 g; 6.64 mmol). 2b was obtained
as an off-white, crystalline powder containing all three stereoisomers
(2.98 g, 56%), mp > 210C. 1H-NMR (300 MHz) in CDCl3 d 1.12–1.33
(m, 18H); 2.97–3.12 (m, 4H); 3.21–3.30 (m, 2H); 3.37–3.44 (m, 2H);
3.90 (bs, 2H); 7.29 (d, J = 9 Hz, 4H); 7.56 (d, J = 9 Hz, 4H); 13C-NMR
(100 MHz) in CDCl3 d 16.64; 19.10; 40.52; 50.33; 53.53; 127.52;
127.82; 139.58; 142.14. Chiral HPLC purification with a Daicel
Chiralpak AD (2 3 25 cm) column and 40:60 heptane:EtOH with
a 7.00 ml/min flow afforded the pure stereoisomers: Rt(R,R)-2b =
25 min, Rt(meso)-2b = 62 min, and Rt(S,S)-2b = 100 min (for
details, see the Supplemental Data). (R,R)-2b: [a]25589 = +31

(c 0.089, CH2Cl2); meso-2b: [a]
25
589 = 0.7 (c 1.156, CH2Cl2);
(S,S)-2b: [a]25589 = 33 (c 0.103, CH2Cl2). (R,R)-2b and meso-2b
were further recrystallized from EtOAc:toluene. Analysis (R,R)-2b:
CHN(C24H36N2O4S20.65 C7H80.10 C2HF3O2); (meso)-2b: CHN
(C24H36N2O4S20.36 C7H80.24 C2HF3O2); (S,S)-2b: CHN(C24H36
N2O4S20.60 C7H160.15 C2HF3O2).Chemistry & Biology 14, 1294–130(R,R)-N,N-(2,20-[Biphenyl-4-40-Diyl]Bis[Propane-2,1-
Diyl])Dimethanesulfonamide, (R,R)-2a
(R)-1g (4.0 g 90% pure; 10.6 mmol, corrected), LiCl (665 mg;
15.6 mmol), Pd(OAc)2 (59 mg; 0.27 mmol), In (600 mg; 5.30 mmol),
and DMF (20 ml) were mixed and stirred 1 hr at 100C. TLC (eluted
with EtOAc) revealed 50% unconverted (R)-1g. Additional Pd(OAc)2
(30 mg; 0.13 mmol) and In (300 mg; 2.65 mmol) were added, and stir-
ring was continued at 100C for 1 hr, after which no (R)-1g could be
seen, as judged by TLC. The reaction was allowed to cool to room tem-
perature, and H2O (50 ml) was added. The aqueous solution was
extracted with EtOAc (3 3 100 ml), and the combined organic phases
were dried (MgSO4) and filtered through silica (35–70 mm, 1 cm layer).
The filtrate was heated to 70C, and hot heptane (80C, 300 ml) was
added. Precipitation was initiated by concentration in vacuo at 70C
of the volume to a total of 300ml, and the reaction was left to crystallize
for 24 hr before filtration to yield (R,R)-2a (0.970 g, 43%), mp 202.6C–
203.4C. [a]25589 = +50 (c 0.156, CH2Cl2);
1H-NMR (300 MHz) and
13C-NMR (75MHz) in CDCl3 are identical to data obtained for 2a. Anal-
ysis CHN(C10H15NO2S0.35 C4H8O2).
Pharmacology
Molecular Biology
The rat AMPA receptor clones GluR1–4 in the vector pGEMHE [28]
were used for preparation of high-expression cRNA transcripts for
functional expression in oocytes. cDNAs were grown in XL1 Blue
bacteria (Stratagene, La Jolla, CA) and were prepared by using column
purification (QIAGEN, Chatsworth, CA). cRNA was synthesized from
cDNA by using the mMessage mMachine T7 transcription kit (Ambion,
Inc., Austin, TX) and were purified by using RNeasy spin columns
(QIAGEN). Restriction and other molecular biological enzymes were
obtained from New England BioLabs (Beverly, MA).
Two-Electrode Voltage Clamp Electrophysiology
X. laevis oocytes were obtained as previously detailed [29]. Recordings
were made at room temperature at holding potentials in the range of
10 to 90 mV, whereas the oocytes were continuously superfused
with Ca2+-free frog Ringer’s solution (in mM: 115 NaCl, 2 KCl, 1.8
BaCl2, 5 HEPES [pH 7.0]). Potentiating compounds were dissolved in
DMSO or DMSO:ethanol (1:1) as 10–30 mM stock solutions, which
were stored at 30C and were freshly diluted into Ca2+-free frog
Ringer’s solution. (S)-Glu (10 mM) was freshly prepared from frozen
500 mM stock solutions. Drugs were coapplied with (S)-Glu and
were added by bath application for 30–60 s until a plateau response
was obtained. The percent potentiation at each concentration of
potentiator was calculated as the percentage increase in the control
current (that given by 10 mM (S)-Glu, which is near the EC50 value at
all of the flip receptors studied).
Data Analysis
Concentration-response curves for potentiators were analyzed by
using Grafit v3.00 (Erithacus Software Ltd., Horley, UK) to determine
the EC50, Hill value (nH), and percent maximum potentiation (%Pmax)
with a logistic equation: %P =%Pmax/(1 + [10
(log[EC50])/10(log [Drug])]nH),
where%P is themeasured percent potentiation. SigmaStat v3.11 (SSI,
San Jose, CA) was employed for the statistical analysis of pharmaco-
logical data. One-way ANOVA with a Bonferroni posttest was used for
statistical comparison of measured parameters, which were consid-
ered significantly different if p < 0.05. For graphical representation of
concentration-response data, responses were pooled from all experi-
ments at a given receptor and potentiator by normalizing the percent
potentiation at each drug concentration to the calculated maximal
potentiation at each individual oocyte.
X-Ray Structure Determination
The point mutation N775S was introduced into the GluR2-S1S2J
construct developed by Armstrong andGouaux [9], thereby converting
the GluR2-S1S2J flop splice form into a flip-like variant. The GluR2-
S1S2J-N775S protein was expressed, refolded, and purified essen-
tially as previously reported [30, 31], with 1 mM (S)-Glu present during
all steps.3, November 2007 ª2007 Elsevier Ltd All rights reserved 1301
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Structural Proof of Dimeric LigandGluR2-S1S2J-N775S was crystallized in complex with (S)-Glu and
(R,R)-2a by the hanging-drop vapor-diffusion method at 7C. The
protein solution contained 12 mg/ml GluR2-S1S2J-N775S in 10 mM
HEPES (pH 7.0), 20 mM NaCl, and 1 mM EDTA. To this solution, an
equal amount of ligand suspension containing 4.5 mM (S)-Glu,
22.5 mM (R,R)-2a, 10 mM HEPES (pH 7.0), 20 mM NaCl, 1 mM
EDTA, and 10% DMSO was added. The protein-ligand suspension
was left at 4C for 1 week and was periodically shaken prior to crystal-
lization experiments. Crystals were obtained in drops consisting of
2 ml protein-ligand suspension and 2 ml reservoir solution of 0.3 M
(NH4)2SO4, 0.1 M CH3CO2Na buffer (pH 5.5), and 25% PEG 4000.
The reservoir volume was 0.5 ml. The crystals grew within 1 week to
a maximum dimension of 0.1 mm.
Crystals of GluR2-S1S2J-N775S in complex with (S)-Glu and (R,R)-
2a were transferred through reservoir solution containing 20% glyc-
erol prior to flash cooling in liquid nitrogen. A complete synchrotron
data set was collected at beamline I911-2 at MaxLab, Lund, Sweden.
Diffraction data were processed with the CCP4 programs MOSFLM
and SCALA [32]. For crystal data and data collection statistics, see
the Supplemental Data.
Two molecules (A and B) are present in the asymmetric unit of the
crystal. The major part (91%) of the amino acid residues of both
molecules A and B were traced with ARP/wARP [33] and the structure
of the nondesensitizing GluR2 ligand-binding core mutant (S1S2J-
L504Y) in complex with (S)-AMPA (PDB code: 1LB8; molecules A
and B) for phasing the data. The remaining residues were built manu-
ally by using COOT [34], except for cloning remnant residues Gly-Ala
and the C-terminal residues 790–792 and 795–796 of molecule A.
Gln735 of molecule A and Met729 of molecule B were located in alter-
native conformations. Two (S)-Glu molecules, 1 (R,R)-2a molecule,
5 sulfate ions, 1 chloride ion, 2 glycerol molecules, and 523 water mol-
ecules were fitted into the electron density. The structure was refined
by using program PHENIX [35]. Between each refinement step, the
structure was inspected and corrected with COOT. The structure
was refined to an R value of 16.8% and an Rfree value of 23.2%. A sum-
mary of structure refinements is presented in Table S1.
The DynDom program [36] was employed for analysis of (S)-Glu-
induced domain closure. The dimer interface was analyzed by using
the Protein-Protein Interaction Server [37]. Figures were prepared
with PyMOL [38].
Supplemental Data
Supplemental Data include descriptions of HPLC methods and appa-
ratus and X-ray crystallography and are available at http://www.
chembiol.com/cgi/content/full/14/11/1294/DC1/.
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